Liu, Kong, Cui, et al. test thymopentin as an adjuvant to oncolytic virotherapy and engineer an oncolytic adenovirus that expresses thymopentin. They show that thymopentin reprograms tumour macrophages and boosts tumour-killing T cells, improving tumour control and durable anti-tumour immunity across multiple models.
- Lingkai Kong
- Kua Liu
- Chunping Jiang
